← Leaderboards
Claudia Ordonez
Children'S Hospital Boston
$792,047
Attributed
$792,047
Total exposure
10
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $350K · FY2005–07$500K$375K$250K$125K$0
'05
'06
'07
Funding mix
By agency
NIH$442,047 · 9
FDA$350,000 · 1
By mechanism
K23$408,485 · 1
R01$350,000 · 1
M01$33,562 · 8
Top collaborators
No co-investigators on record.
Most similar at Children'S Hospital Boston
Same institution · by research overlap
- Gary Arthur Silverman$22,624,651
- David A Waltz$84,936
- Craig J. Gerard$12,629,224
- Donald E Ingber$21,971,527
- Mark Dovey$100,085
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchCystic FibrosisHuman SubjectSputumHuman Therapy EvaluationInflammationPatient Oriented ResearchRespiratory TherapyMetabolism Disorder DiagnosisElastasesAlpha 1 AntitrypsinDiagnostic Respiratory LavageRespiratory Disorder DiagnosisLung DisorderRespiratory FunctionAminoglycoside AntibioticsPathologic ProcessDrug MetabolismDrug Administration Rate /DurationDrug Screening /EvaluationDiagnosis Design /EvaluationFunctional /Structural GenomicsMicroorganism CultureCombination Chemotherapy
Grant awards (21)
Phase 2 study of VX-770 in Cystic Fibrosis Subjectswith G551D$350,000
R01 · FY2007 · FD · contact PI
P aeruginosa virulence in cystic fibrosis lung disease$154,683
K23 · FY2006 · HL · contact PI
ASSESSMENT OF INDUCED SPUTUM AS A TOOL TO EVALUATE ANTI-INFLAMMATORY AGENTS$8,124
M01 · FY2006 · RR · contact PI
FORMULA FORIFIED W/ DOCOSAHEXAENOIC ACID (DHA) IN INFANTS W/ CYSTIC FIBROSIS$3,693
M01 · FY2006 · RR · contact PI
P aeruginosa virulence in cystic fibrosis lung disease$127,443
K23 · FY2005 · HL
TISSUE BANK FOR PULMONARY DISEASES$726
M01 · FY2005 · RR
USE OF SPUTUM IND TO STUDY INFECTION &INFLAM IN CHILD W/CF PHS I&II$726
M01 · FY2005 · RR
P. aeruginosa virulence in cystic fibrosis lung disease$126,359
K23 · FY2004 · HL
Cystic Fibrosis Once Daily Aminoglycoside Clinical Trial (CFODACT)$18,431
M01 · FY2004 · RR
Tissue Bank for Pulmonary Diseases$931
M01 · FY2004 · RR
Study of Airway Inflammation in Subjects with Cystic Fibrosis$559
M01 · FY2004 · RR
USE OF SPUTUM IND. TO STUDY INFECTION &INFLAM. IN CHILD. W/C.F. PHS I&II$186
M01 · FY2004 · RR
Phase I trial comparing two delivery methods and doses of TOBI in CF patients$186
M01 · FY2004 · RR
AIRWAY INFLAMMATION IN CYSTIC FIBROSIS$0
M01 · FY2002 · RR
FREE ELASTASE IN BAL FLUID IN CYSTIC FIBROSIS PATIENTS$0
M01 · FY2002 · RR
FREE ELASTASE IN BAL FLUID IN CYSTIC FIBROSIS PATIENTS$0
M01 · FY2001 · RR
AIRWAY INFLAMMATION IN CYSTIC FIBROSIS$0
M01 · FY2001 · RR
AIRWAY INFLAMMATION IN CYSTIC FIBROSIS$0
M01 · FY2001 · RR
FREE ELASTASE IN BAL FLUID IN CYSTIC FIBROSIS PATIENTS$0
M01 · FY2001 · RR
FREE ELASTASE IN BAL FLUID IN CYSTIC FIBROSIS PATIENTS$0
M01 · FY2000 · RR
AIRWAY INFLAMMATION IN CYSTIC FIBROSIS$0
M01 · FY2000 · RR